Treace Medical Concepts, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023 at 04:05 pm EDT
Share
Treace Medical Concepts, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 41.95 million compared to USD 29.97 million a year ago. Net loss was USD 12.27 million compared to USD 17.23 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.31 a year ago.
For the six months, sales was USD 84.15 million compared to USD 59.01 million a year ago. Net loss was USD 25.73 million compared to USD 26.27 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.48 a year ago.
Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
TREACE MEDICAL CONCEPTS, INC. 
